目的 观察血塞通注射液联合比索洛尔治疗冠心病心力衰竭的临床疗效。方法 选取2013年6月-2015年3月儋州市第三人民医院收治的冠心病心力衰竭患者72例，随机分为对照组和治疗组，每组各36例。对照组口服富马酸比索洛尔片，初始剂量为1.25 g/次，1次/d；若耐受则1周后，增加1.25 mg/次直至5 mg/次；若仍能耐受则每月增加2.5 mg/次直至10 mg/次。治疗组在对照组基础上静脉滴注血塞通注射液，500 mg加入到5%葡萄糖溶液250 mL中，1次/d。两组患者均治疗2个月。观察两组的临床疗效，比较两组患者心脏功能及血液流变学情况。结果 治疗后，对照组和治疗组的总有效率分别为77.8%、91.7%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的红细胞压积、血浆黏度、全血黏度高切及全血黏度低切均显著降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗组这些观察指标的降低程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的左室射血分数（LVEF）均显著升高，而左室收缩末期容积（LVESV）和左室舒张末期容积（LVEDV）均显著降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 血塞通注射液联合比索洛尔治疗冠心病心力衰竭具有较好的临床疗效，能增强心脏功能，改善血液流变学情况，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Xuesaitong Injection combined with bisoprolol in treatment of coronary heart disease complicated with heart failure. Methods Patients (72 cases) with coronary heart disease complicated with heart failure in Danzhou Third People's Hospital from June 2013 to March 2015 were randomly divided into the control and treatment groups, and each group had 36 cases. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, starting dosage 1.25 mg/time, once daily, and if the patients could tolerate it, the dosage was increased for 1.25 mg/time up to 5 mg/time after 1 week, and if the patients can still tolerate it, the dosage was increased for 2.5 mg/time each month up to 10 mg/time. Patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 500 mg added to 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and heart function and blood rheology in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.8% and 91.7%, respectively, and there was difference between two groups (P<0.05). After treatment, hematocrit, plasma viscosity, whole high viscosity, and low shear whole blood viscosity in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the LVEF in two groups were significantly increased, but LVESV and LVEDV in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xuesaitong Injection combined with bisoprolol has the clinical curative effect in treatment of coronary heart disease complicated with heart failure, and can enhance heart function, improve blood rheology, which has a certain clinical application value.